Synbiotics Gut Health Randomized Trial Evidence Table

Structured evidence table for Synbiotics Gut Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Synbiotics Gut Health Randomized TrialWith its rising incidence at younger ages and its association with cancer risk, NAFLD has become a growing health concern ().3Attieh Philippe (2026)MASLD beyond the liver: decoding the gut–genetic–metabolic nexus
Synbiotics Gut Health Randomized TrialReflecting this broader understanding, the terminology has shifted, with NAFLD now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), and NASH as metabolic dysfunction-associated steatohepatitis (MASH) ().3Attieh Philippe (2026)MASLD beyond the liver: decoding the gut–genetic–metabolic nexus
Synbiotics Gut Health Randomized TrialBy integrating current evidence, we highlight the role of microbiota, metabolic dysregulation, and immune signaling in disease progression, while outlining promising diagnostic biomarkers and therapeutic strategies to guide future research and clinical management.3Attieh Philippe (2026)MASLD beyond the liver: decoding the gut–genetic–metabolic nexus
Synbiotics Gut Health Randomized Trial1 2 3 4 5 6 7 Nonalcoholic fatty liver disease (NAFLD) is a metabolic liver disorder marked by excessive triglyceride (TG) accumulation in hepatocytes ().3Attieh Philippe (2026)MASLD beyond the liver: decoding the gut–genetic–metabolic nexus
Synbiotics Gut Health Randomized TrialHowever, existing evidence does not prove that microbiome changes are a direct source of these adaptations as exercise, food, and other host factors may all contribute at the same time ().3Zhang Xinbao (2026)Microbiome-based nutrition and the gut–muscle axis: emerging perspectives for athletic performance and recovery
Synbiotics Gut Health Randomized TrialBioactive plant chemicals called polyphenols, which are found in large quantities in fruits, vegetables, and teas, additionally regulate this relationship by selectively enriching and functioning as prebiotic substrates ().3Zhang Xinbao (2026)Microbiome-based nutrition and the gut–muscle axis: emerging perspectives for athletic performance and recovery
Synbiotics Gut Health Randomized TrialSCFAs may affect AMPK, PGC-1α, and associated metabolic pathways, according to experimental studies.3Zhang Xinbao (2026)Microbiome-based nutrition and the gut–muscle axis: emerging perspectives for athletic performance and recovery
Synbiotics Gut Health Randomized Trial1 2 3 4 The dynamic interaction of training load, recuperation, diet, and biological resilience determines athletic efficiency.3Zhang Xinbao (2026)Microbiome-based nutrition and the gut–muscle axis: emerging perspectives for athletic performance and recovery
topicSynbiotics Gut Health Randomized Trial
claimWith its rising incidence at younger ages and its association with cancer risk, NAFLD has become a growing health concern ().
evidence level3
citationAttieh Philippe (2026)
sourceMASLD beyond the liver: decoding the gut–genetic–metabolic nexus
topicSynbiotics Gut Health Randomized Trial
claimReflecting this broader understanding, the terminology has shifted, with NAFLD now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), and NASH as metabolic dysfunction-associated steatohepatitis (MASH) ().
evidence level3
citationAttieh Philippe (2026)
sourceMASLD beyond the liver: decoding the gut–genetic–metabolic nexus
topicSynbiotics Gut Health Randomized Trial
claimBy integrating current evidence, we highlight the role of microbiota, metabolic dysregulation, and immune signaling in disease progression, while outlining promising diagnostic biomarkers and therapeutic strategies to guide future research and clinical management.
evidence level3
citationAttieh Philippe (2026)
sourceMASLD beyond the liver: decoding the gut–genetic–metabolic nexus
topicSynbiotics Gut Health Randomized Trial
claim1 2 3 4 5 6 7 Nonalcoholic fatty liver disease (NAFLD) is a metabolic liver disorder marked by excessive triglyceride (TG) accumulation in hepatocytes ().
evidence level3
citationAttieh Philippe (2026)
sourceMASLD beyond the liver: decoding the gut–genetic–metabolic nexus
topicSynbiotics Gut Health Randomized Trial
claimHowever, existing evidence does not prove that microbiome changes are a direct source of these adaptations as exercise, food, and other host factors may all contribute at the same time ().
evidence level3
citationZhang Xinbao (2026)
sourceMicrobiome-based nutrition and the gut–muscle axis: emerging perspectives for athletic performance and recovery
topicSynbiotics Gut Health Randomized Trial
claimBioactive plant chemicals called polyphenols, which are found in large quantities in fruits, vegetables, and teas, additionally regulate this relationship by selectively enriching and functioning as prebiotic substrates ().
evidence level3
citationZhang Xinbao (2026)
sourceMicrobiome-based nutrition and the gut–muscle axis: emerging perspectives for athletic performance and recovery
topicSynbiotics Gut Health Randomized Trial
claimSCFAs may affect AMPK, PGC-1α, and associated metabolic pathways, according to experimental studies.
evidence level3
citationZhang Xinbao (2026)
sourceMicrobiome-based nutrition and the gut–muscle axis: emerging perspectives for athletic performance and recovery
topicSynbiotics Gut Health Randomized Trial
claim1 2 3 4 The dynamic interaction of training load, recuperation, diet, and biological resilience determines athletic efficiency.
evidence level3
citationZhang Xinbao (2026)
sourceMicrobiome-based nutrition and the gut–muscle axis: emerging perspectives for athletic performance and recovery

Source documents

  1. MASLD beyond the liver: decoding the gut–genetic–metabolic nexus
  2. Microbiome-based nutrition and the gut–muscle axis: emerging perspectives for athletic performance and recovery